

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) (E)-2-(5-Chlorothien-2-yl)-N-[(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]ethanesulfonamide in substantially crystalline form having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.1-9.2 (± 0.1), 16.0-16.1 (± 0.1), 18.0-18.2 (± 0.1), and 18.3-18.4 (± 0.1) degrees.
2. (Original) The substantially crystalline form as claimed in claim 1 in the form of needle-shaped crystals.
3. (Original) The substantially crystalline form as claimed in claim 1 in the form of lath-shaped crystals.
4. (Original) The substantially crystalline form as claimed in claim 1 in the form of a mixture of needle-shaped and lath-shaped crystals.
5. (Previously Presented) The substantially crystalline form as claimed in claim 1 wherein the melting point is greater than 160°C.
6. (Previously Presented) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at two or more positions selected from the group consisting of 9.1-9.2 (± 0.1), 16.0-16.1 (± 0.1), 18.0-18.2 (± 0.1), and 18.3-18.4 (± 0.1) degrees.
7. (Previously Presented) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern

comprises 2 theta angles at three or more positions selected from the group consisting of 9.1-9.2 (± 0.1), 16.0-16.1 (± 0.1), 18.0-18.2 (± 0.1), and 18.3-18.4 (± 0.1) degrees.

8. (Previously Presented) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at all four positions selected from the group consisting of 9.1-9.2 (± 0.1), 16.0-16.1 (± 0.1), 18.0-18.2 (± 0.1), and 18.3-18.4 (± 0.1) degrees.
9. (Cancelled)
10. (Cancelled).
11. (Cancelled).
12. (Cancelled).
13. (Previously Presented) A method for the preparation of (E)-2-(5-chlorothiophen-2-yl)-N-((3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)ethanesulfonamide in substantially crystalline form which method comprises crystallisation of (E)-2-(5-chlorothiophen-2-yl)-N-((3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)ethanesulfonamide from an organic solution, optionally in the presence of water.
14. (Original) A method as claimed in claim 13 wherein the organic solution selected from: an aromatic hydrocarbon, a cycloalkane, an ester, an alcohol or a ketone, or a mixture thereof.
15. (Cancelled).
16. (Cancelled).

PG5042USW

17. (Cancelled).

18. (Cancelled).

19. (Cancelled).